Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Checkpoint Therapeutics Trading Down 9.3 %

Shares of Checkpoint Therapeutics stock opened at $3.43 on Thursday. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97. The company’s 50-day moving average price is $2.82 and its two-hundred day moving average price is $2.35. The stock has a market cap of $154.42 million, a PE ratio of -1.86 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in Checkpoint Therapeutics during the 2nd quarter worth about $34,000. Gladstone Institutional Advisory LLC raised its holdings in shares of Checkpoint Therapeutics by 141.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares during the period. Magnus Financial Group LLC lifted its position in shares of Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares in the last quarter. 180 Wealth Advisors LLC acquired a new position in Checkpoint Therapeutics in the 2nd quarter worth approximately $96,000. Finally, Choreo LLC grew its position in Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.